Exploring Fecal Microbiota Transplantation: Potential Benefits, Associated Risks, and Challenges in Cancer Treatment
Cancer Reports · 2026
DOI: 10.1002/cnr2.70455 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Reports, 2026. Verfasst von Aswathi Ramesh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Advanced Biotherapeutics and Regenerative Medicine, Faculty of Research, Chettinad Hospital and Research Institute, Chettinad Academy of R…. Hauptthemen laut MEDLINE: Fecal Microbiota Transplantation, Neoplasms, Gastrointestinal Microbiome. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Fecal microbiota transplantation (FMT) has emerged as a groundbreaking strategy for modulating the gut microbiome and improving cancer treatment outcomes. This review synthesizes the current evidence on the role of FMT in oncology, focusing on its potential to enhance the efficacy of immunotherapy, restore microbiome homeostasis, and mitigate cancer‐associated complications. Recent Findings Preclinical and clinical studies have demonstrated that FMT can reprogram the tumor microenvironment, augment immune checkpoint inhibitor responses, and reduce chemotherapy‐induced toxicity. However, risks such as pathogen transmission, immune dysregulation, and unintended microbial shifts necessitate rigorous donor screening and a personalized approach. Challenges in standardization, regulatory frameworks, and mechanistic understanding further complicate their clinical translation. Emerging innovations, including precision microbial consortia, synthetic biology, and biomarker‐driven strategies, have the potential to address these limitations.
Conclusion
While FMT holds transformative potential in cancer care, its integration into oncological practice requires robust clinical validation, long‐term safety assessments, and interdisciplinary collaboration to harness its full therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre for Advanced Biotherapeutics and Regenerative Medicine, Faculty of Research, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Chennai, India.
- Centre for Herbal Pharmacology and Environmental Sustainability, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Chennai, India.
- Department of Natural and Applied Sciences, Nexus Institute of Research and Innovation (NIRI), Lalitpur, Nepal.
- Department of Basic Medical and Dental Sciences, College of Dentistry, Gulf Medical University, Ajman, UAE.
ORCID-Profile: Rajasekaran Subbarayan, Rupendra Shrestha
Zitieren
APA
Ramesh, A., Subbarayan, R., Shrestha, R., & Adtani, P. N. (2026). Exploring Fecal Microbiota Transplantation: Potential Benefits, Associated Risks, and Challenges in Cancer Treatment. Cancer Reports. https://doi.org/10.1002/cnr2.70455
Vancouver
Ramesh A, Subbarayan R, Shrestha R, Adtani PN. Exploring Fecal Microbiota Transplantation: Potential Benefits, Associated Risks, and Challenges in Cancer Treatment. Cancer Reports. 2026. doi:10.1002/cnr2.70455
BibTeX
@article{Ramesh2026,
author = {Ramesh, Aswathi and Subbarayan, Rajasekaran and Shrestha, Rupendra and Adtani, Pooja Narain},
title = {Exploring Fecal Microbiota Transplantation: Potential Benefits, Associated Risks, and Challenges in Cancer Treatment},
journal = {Cancer Reports},
year = {2026},
doi = {10.1002/cnr2.70455}
}
EUVIMED